drugset / Trial / NCT00157326

Tadalafil in Subjects With Mild to Moderate Hypertension

NCT00157326

Phase 2 Completed 180 enrolled Eli Lilly and Company ICOS Corporation · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

Purpose: The primary objective of this study is to evaluate the efficacy and safety of tadalafil when administered once daily at doses of 5 and 20 mg to adult subjects for 8 weeks with mild to moderate hypertension.

Timeline

Start
2005-09
Primary completion
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Tadalafil Small molecule 5 mg
Subject Tadalafil Small molecule 20 mg

Indications